Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

Temporal Effects of Quercetin on Tight Junction Barrier Properties and Claudin Expression and Localization in MDCK II Cells.

Gamero-Estevez E, Andonian S, Jean-Claude B, Gupta I, Ryan AK.

Int J Mol Sci. 2019 Oct 2;20(19). pii: E4889. doi: 10.3390/ijms20194889.

2.

Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.

Sharifi Z, Abdulkarim B, Meehan B, Rak J, Daniel P, Schmitt J, Lauzon N, Eppert K, Duncan HM, Petrecca K, Guiot MC, Jean-Claude B, Sabri S.

Clin Cancer Res. 2019 Dec 15;25(24):7594-7608. doi: 10.1158/1078-0432.CCR-19-0955. Epub 2019 Sep 20.

PMID:
31540977
3.

Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation.

Chaddad A, Kucharczyk MJ, Daniel P, Sabri S, Jean-Claude BJ, Niazi T, Abdulkarim B.

Front Oncol. 2019 May 21;9:374. doi: 10.3389/fonc.2019.00374. eCollection 2019. Review.

4.

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities.

Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim BS.

Front Oncol. 2019 Feb 4;9:41. doi: 10.3389/fonc.2019.00041. eCollection 2019. Review.

5.

Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.

Tian J, Raffa FA, Dai M, Moamer A, Khadang B, Hachim IY, Bakdounes K, Ali S, Jean-Claude B, Lebrun JJ.

Br J Cancer. 2018 Dec;119(12):1495-1507. doi: 10.1038/s41416-018-0287-3. Epub 2018 Nov 28.

6.

Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O6-methylguanine-DNA methyltransferase with a double arm hybrid molecule.

Rupp M, Mouhri ZS, Williams C, Jean-Claude BJ.

Oncotarget. 2018 Oct 12;9(80):35041-35055. doi: 10.18632/oncotarget.25120. eCollection 2018 Oct 12.

7.

Examination of VDR/RXR/DRIP205 Interaction, Intranuclear Localization, and DNA Binding in Ras-Transformed Keratinocytes and Its Implication for Designing Optimal Vitamin D Therapy in Cancer.

Jusu S, Presley JF, Williams C, Das SK, Jean-Claude B, Kremer R.

Endocrinology. 2018 Mar 1;159(3):1303-1327. doi: 10.1210/en.2017-03098.

PMID:
29300860
8.

Performance of Knowledge-Based Radiation Therapy Planning for the Glioblastoma Disease Site.

Chatterjee A, Serban M, Abdulkarim B, Panet-Raymond V, Souhami L, Shenouda G, Sabri S, Jean-Claude B, Seuntjens J.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):1021-1028. doi: 10.1016/j.ijrobp.2017.07.012. Epub 2017 Jul 14.

PMID:
28870791
9.
11.

Modifiable Risk Factors for Delirium in Critically Ill Trauma Patients: A Multicenter Prospective Study.

Duceppe MA, Williamson DR, Elliott A, Para M, Poirier MC, Delisle MS, Deckelbaum D, Razek T, Desjardins M, Bertrand JC, Bernard F, Rico P, Burry L, Frenette AJ, Perreault M.

J Intensive Care Med. 2019 Apr;34(4):330-336. doi: 10.1177/0885066617698646. Epub 2017 Mar 24.

PMID:
28335673
12.

Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.

Goodfellow E, Senhaji Mouhri Z, Williams C, Jean-Claude BJ.

Bioorg Med Chem Lett. 2017 Feb 1;27(3):688-694. doi: 10.1016/j.bmcl.2016.09.054. Epub 2016 Sep 22.

PMID:
28003142
13.

Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.

Patyka M, Sharifi Z, Petrecca K, Mansure J, Jean-Claude B, Sabri S.

Oncotarget. 2016 Sep 13;7(37):60245-60269. doi: 10.18632/oncotarget.11197.

14.

Validation and comparison of CAM-ICU and ICDSC in mild and moderate traumatic brain injury patients.

Frenette AJ, Bebawi ER, Deslauriers LC, Tessier AA, Perreault MM, Delisle MS, Bertrand JC, Desjardins M, Rico P, Khwaja K, Burry LD, Bernard F, Williamson DR.

Intensive Care Med. 2016 Jan;42(1):122-3. doi: 10.1007/s00134-015-3964-1. Epub 2015 Jul 14. No abstract available.

PMID:
26170098
15.

Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis.

Tedeschi AL, Eslami Z, Garoufalis E, Saleh RR, Omeroglu A, Altinel G, Ait-Tihyaty M, Jean-Claude B, Mihalcioiu C.

Onco Targets Ther. 2015 Apr 21;8:911-9. doi: 10.2147/OTT.S71089. eCollection 2015.

16.

ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model.

Heravi M, Kumala S, Rachid Z, Jean-Claude BJ, Radzioch D, Muanza TM.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):399-406. doi: 10.1016/j.ijrobp.2015.01.026. Epub 2015 Mar 27.

PMID:
25823448
17.

Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.

Rao S, Larroque-Lombard AL, Peyrard L, Thauvin C, Rachid Z, Williams C, Jean-Claude BJ.

PLoS One. 2015 Feb 6;10(2):e0117215. doi: 10.1371/journal.pone.0117215. eCollection 2015.

18.

Positional isomerization of a non-cleavable combi-molecule dramatically altered tumor cell response profile.

Huang Y, Rachid Z, Peyrard L, Senhaji Mouhri Z, Williams C, Jean-Claude BJ.

Chem Biol Drug Des. 2015 Feb;85(2):153-62. doi: 10.1111/cbdd.12402. Epub 2014 Sep 25.

PMID:
25092264
19.

ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.

Ait-Tihyaty M, Rachid Z, Larroque-Lombard AL, Jean-Claude BJ.

Invest New Drugs. 2013 Dec;31(6):1409-23.

PMID:
23959266
20.

Biological effects of AL622, a molecule rationally designed to release an EGFR and a c-Src kinase inhibitor.

Larroque-Lombard AL, Ning N, Rao S, Lauwagie S, Halaoui R, Coudray L, Huang Y, Jean-Claude BJ.

Chem Biol Drug Des. 2012 Dec;80(6):981-91. doi: 10.1111/cbdd.12043.

PMID:
22943437

Supplemental Content

Loading ...
Support Center